#ThinkSabio Latest News
First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema.
Intellia expects to complete enrollment in 2H’25 and submit a BLA in 2026
First Patient Dosed in the HAELO Phase 3 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema.
Intellia expects to complete enrollment in 2H’25 and submit a BLA in 2026
